Clinical Trial Update: Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating tislelizumab combined with chemotherapy with or without bevacizumab in EGFR-mutated, TKI-resistant non-squamous non-small cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN